ARMP — Armata Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $143.89m
- $403.45m
- $4.90m
Brief: Armata Pharmaceuticals Announces Clearance Of IND For Prosthetic Joint Infections
AMEX RESUMED ARMATA PHRMCUTCL
AMEX HALT ADDITIONAL INFORMATION LAST 3.640000
AMEX RESUMED ARMATA PHRMCUTCL
AMEX HALT ADDITIONAL INFORMATION LAST 3.675000
Brief: Armata Pharma Doses First Patient In Phase 1B/2A Study Of Treatment Of Bacteremia Due To Staphylococcus Aureus
Brief: Armata Pharmaceuticals Announces Q1 2022 Results
Brief: Armata Pharmaceuticals Files Prospectus Related To Disposition Of Up To 2.1 Million
Brief: Armata Pharmaceuticals - On March 25, Steve Martin Notified He Intends To Retire As CFO & Senior Vice President Effective As Of June 30, 2022
Brief: Armata Pharma Reports Q4 And Full Year 2021 Results
Brief: Armata Pharmaceuticals Announces Clearance Of Investigational New Drug Application For Phase 2 Trial Of AP-Pa02
Brief: Armata Pharmaceuticals Announces $45 Million Investment To Support Advancement Of The Company's Bacteriophage Development
Brief: Armata Pharmaceuticals Provides Update On Pseudomonas Respiratory Programs
Brief: Armata Pharma Gets FDA IND Clearance For Phase 1B/2A Study Of Staphylococcus Aureus Bacteremia Treatment
Brief: Armata Pharmaceuticals Posts Q3 Loss Per Share Of 22 Cents
Brief: Armata Pharma Enters Into New Lease To Build Research And Development And GMP Manufacturing Facility In Los Angeles
AMEX RESUMED ARMATA PHRMCUTCL
AMEX HALT ADDITIONAL INFORMATION LAST 4.070000
AMEX RESUMED ARMATA PHRMCUTCL